Exome and Multi-Site Bulk and scRNA-seq Profiling of Pleural Mesothelioma
This study comprehensively profiles pleural mesothelioma (PM) using integrated bulk DNA sequencing [whole-exome sequencing (WES)], bulk RNA-sequencing (RNA-seq), single-cell RNA-sequencing (scRNA-seq), optical genome mapping, spatial transcriptomics, and spatial proteomics. The goals are to characterize malignant and stromal cell states, identify malignant phenotypes, define tumor microenvironmental correlates, and evaluate associations with clinical outcomes and survival.
Primary Objectives
- Map malignant cell programs and epithelial–mesenchymal gradients across anatomic sites.
- Define stromal and immune microenvironment states using scRNA-seq and spatial assays.
- Integrate multi-omic data to identify structural variants, CNVs, SNVs, and transcriptomic programs to determine relationship with malignant cell phenotype.
- Evaluate prognostic significance of malignant programs in independent cohorts.
Study Design
A retrospective cohort of surgical PM resections collected at Brigham and Women's Hospital from 2015–2025 was analyzed under IRB protocol DFCI #98-063. Multi-site pleural sampling was performed during radical pleurectomy/decortication, with samples allocated to single-cell transcriptomics, bulk RNA-seq, WES, optical genome mapping, and histopathology.
Raw reads for bulk RNA, single cell RNA, and exome sequencing and optical genome mapping structural variant calls are included in this dbGaP submission. Relevant counts matrices for bulk RNA (NCBI GEO GSE327166) and single cell RNA (NCBI GEO GSE327167) may be accessed directly via the NCBI GEO data repository. Spatial transcriptomics data (NCBI GEO GSE327347) may also be accessed directly via the NCBI GEO data repository.
Relevant Genes
MEST: MEST was identified as a robust transcript and protein biomarker for pleural mesothelioma cells with the newly described 'uncommitted' molecular phenotype. This phenotype and associated positive staining for MEST using IHC carries a poor prognosis for pleural mesothelioma patients.
MSLN: We identified MSLN was identified as a robust transcript and protein biomarker for pleural mesothelioma cells with 'epithelioid' molecular phenotype. This phenotype and associated positive staining for MSLN protein using IHC carries a positive prognosis for pleural mesothelioma patients.
TGFB1 and TGFB3: Both TGFB1 and TGFB3 were associated with sarcomatoid and uncommitted molecular states of pleural mesothelioma.
TGFBI: Fibroblasts were identified with high TGFBI expression in more mesenchymal pleural mesothelioma tumors (sarcomatoid and uncommitted molecular state). The ratio of TGFBI to IGF1 correlated with a negative prognosis suggesting these fibroblasts may represent a negative prognostic factor in pleural mesothelioma.
IGF1: Fibroblasts were identified with high IGF1 expression in more mesenchymal pleural mesothelioma tumors (sarcomatoid and uncommitted molecular state). The ratio of TGFBI to IGF1 correlated with a negative prognosis suggesting these fibroblasts may represent a positive prognostic factor in pleural mesothelioma.
WNT2B: WNT2B was significantly differentially expressed in pleural mesothelioma tumors with predominantly epithelioid molecular state with significant interactions between malignant cells and their microenvironment.
AXL: AXL was significantly differentially expressed in pleural mesothelioma tumors with predominantly sarcomatoid molecular state with significant interactions between malignant cells and their microenvironment.
- Type: Aggregate Genomic Data
- Archive: The database of Genotypes and Phenotypes (dbGaP)
